We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A phase 2a trial of Sensorion’s vertigo seliforant has met its primary tolerability endpoint. The trial found the histamine type 4 receptor antagonist had .....